Malignant tumor has been a major threat. Currently around 4 million new cases are reported every year in China.
The small molecule anti-tumor drugs are developed against oncogenes. Once absorbed, these drugs specifically bind to their targets, leading to the apoptosis induction and proliferation inhibition of tumor cells. Targeted drugs show much higher specificity, better efficacy, and less toxicity, as compared to conventional chemotherapeutic agents.

The chronic kidney disease (CKD) is a common chronic disease in China, and current patient population is about 119.5 million. The progression of CKD is affected by multiple factors, including hemodynamic changes, metabolic disorders, inflammation, and fibrosis. In addition to existing prophylactic approaches of lowering blood pressure (controlling hemodynamics) and blood sugar (improving metabolism), further novel effective therapeutics are needed to slow down CKD progression. We are working towards this goal by developing small molecule drugs to inhibit hyperactivation of mineralocorticoid receptors and overexpression of inflammatory factors and cytokines, to ultimately reduce inflammation and fibrosis

The small molecule anti-bacterial drugs interfere with the metabolism of pathogenic microorganisms, inhibiting critical synthetic pathways for nucleic acids, proteins, cell membranes and cell wall. As compared to conventional anti-bacterial agents, the novel molecules we’ve developed are specifically designed to tackle multidrug resistance. They showed broader spectrum, higher bactericidal activity, and better safety profile in human. These molecules are effective against several multidrug resistant (MDR) bacteria, providing a potentially better option for treating MDR bacterial infections and severe systemic infections.